ARDX

Company Overview — What Does ARDELYX, INC. Do?

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. ARDELYX, INC. (ARDX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael G. Raab and employs approximately 90 people, headquartered in Fremont, California. With a market capitalization of $1.5B, ARDX is one of the notable companies in the Healthcare sector.

ARDELYX, INC. (ARDX) Stock Rating — Reduce (April 2026)

As of April 2026, ARDELYX, INC. receives a Reduce rating with a composite score of 39.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ARDX ranks #2,810 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ARDELYX, INC. ranks #390 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ARDX Stock Price and 52-Week Range

ARDELYX, INC. (ARDX) currently trades at $6.15. The stock gained $0.02 (0.3%) in the most recent trading session. The 52-week high for ARDX is $8.40, which means the stock is currently trading -26.8% from its annual peak. The 52-week low is $3.21, putting the stock 91.6% above its annual trough. Recent trading volume was 1.1M shares, reflecting moderate market activity.

Is ARDX Overvalued or Undervalued? — Valuation Analysis

ARDELYX, INC. (ARDX) carries a value factor score of 31/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 8.74x, versus the sector average of 2.75x. The price-to-sales ratio is 3.84x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ARDX trades at 31.69x EV/EBITDA, versus 6.34x for the sector.

At current multiples, ARDELYX, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ARDELYX, INC. Profitability — ROE, Margins, and Quality Score

ARDELYX, INC. (ARDX) earns a quality factor score of 32/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -37.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -12.4% versus the sector average of -33.1%.

On a margin basis, ARDELYX, INC. reports gross margins of 87.8%, compared to 71.5% for the sector. The operating margin is -14.3% (sector: -66.1%). Net profit margin stands at -19.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 50.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ARDX Debt, Balance Sheet, and Financial Health

ARDELYX, INC. has a debt-to-equity ratio of 121.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 4.31x, indicating strong short-term liquidity. Total debt on the balance sheet is $203M. Cash and equivalents stand at $43M.

ARDX has a beta of 0.77, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for ARDELYX, INC. is 45/100, reflecting average volatility within the normal range for its sector.

ARDELYX, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ARDELYX, INC. reported revenue of $380M and earnings per share (EPS) of $-0.26. Net income for the quarter was $-62M. Gross margin was 87.8%. Operating income came in at $-44M.

In FY 2025, ARDELYX, INC. reported revenue of $407M and earnings per share (EPS) of $-0.26. Net income for the quarter was $-62M. Gross margin was 90.3%. Revenue grew 22.1% year-over-year compared to FY 2024. Operating income came in at $-41M.

In Q3 2025, ARDELYX, INC. reported revenue of $110M and earnings per share (EPS) of $0.00. Net income for the quarter was $-969,000. Gross margin was 96.4%. Revenue grew 12.3% year-over-year compared to Q3 2024. Operating income came in at $5M.

In Q2 2025, ARDELYX, INC. reported revenue of $98M and earnings per share (EPS) of $-0.08. Net income for the quarter was $-19M. Gross margin was 87.3%. Revenue grew 33.4% year-over-year compared to Q2 2024. Operating income came in at $-14M.

Over the past 8 quarters, ARDELYX, INC. has demonstrated a growth trajectory, with revenue expanding from $73M to $380M. Investors analyzing ARDX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ARDX Dividend Yield and Income Analysis

ARDELYX, INC. (ARDX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ARDX Momentum and Technical Analysis Profile

ARDELYX, INC. (ARDX) has a momentum factor score of 49/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.

ARDX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ARDELYX, INC. (ARDX) ranks #390 out of 838 stocks based on the Blank Capital composite score. This places ARDX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ARDX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ARDX vs S&P 500 (SPY) comparison to assess how ARDELYX, INC. stacks up against the broader market across all factor dimensions.

ARDX Next Earnings Date

No upcoming earnings date has been announced for ARDELYX, INC. (ARDX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ARDX? — Investment Thesis Summary

The quantitative profile for ARDELYX, INC. suggests caution. The quality score of 32/100 flags below-average profitability. The value score of 31/100 indicates premium valuation.

In summary, ARDELYX, INC. (ARDX) earns a Reduce rating with a composite score of 39.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ARDX stock.

Related Resources for ARDX Investors

Explore more research and tools: ARDX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ARDX head-to-head with peers: ARDX vs AZN, ARDX vs SLGL, ARDX vs VMD.